MAPT and Alzheimer disease: Notable strengths of this study include the simultaneous metabolicprofiling of a relatively high number of analytes (18 metabolites)in time-linked human serum and CSF samples from all participants andthe inclusion of multiple nervous system pathologies: LBD, 4R-Tau,MSA, and AD.